What is AbCellera Biologics Inc.'s SG&A?

AbCellera Biologics Inc. (ABCL) reported SG&A of $12.33M in Q1 2026.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

AbCellera Biologics Inc. ABCL SG&A

SG&A at other companies

Twist Bioscience CorporationTWST

$76.09M+19.5%

PrecigenPGEN

$21.05M+70.3%

ADMA BiologicsADMA

$26.74M+11.1%

Bristol-Myers SquibbBMY

$1.62B+2.1%

AbbVieABBV

$3.58B+8.7%

BridgeBio PharmaBBIO

$163.9M+54.1%

Other financials

Income statement

See full

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Balance sheet

See full

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Cash flow

See full

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Valuation

See full

Market cap$1.72B+59.2%

Enterprise value$1.76B+100.0%

P/S21.7×-25.0×

Profitability

See full

Operating margin-267.6%-120pp

Net margin-181.7%-77.9pp

FCF margin-238.9%-90.9pp

Returns & leverage

See full

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbCellera Biologics Inc.'s SG&A?: AbCellera Biologics Inc. (ABCL) reported SG&A of $12.33M in Q1 2026.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.